Potential of Induced Pluripotent Stem Cells (iPSCs) for Treating Age-Related Macular Degeneration (AMD)
The field of stem cell biology has rapidly evolved in the last few decades. In the area of regenerative medicine, clinical applications using stem cells hold the potential to be a powerful tool in the treatment of a wide variety of diseases, in particular, disorders of the eye. Embryonic stem cells...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2016-12-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2073-4409/5/4/44 |
| _version_ | 1797714939174977536 |
|---|---|
| author | Mark Fields Hui Cai Jie Gong Lucian Del Priore |
| author_facet | Mark Fields Hui Cai Jie Gong Lucian Del Priore |
| author_sort | Mark Fields |
| collection | DOAJ |
| description | The field of stem cell biology has rapidly evolved in the last few decades. In the area of regenerative medicine, clinical applications using stem cells hold the potential to be a powerful tool in the treatment of a wide variety of diseases, in particular, disorders of the eye. Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are promising technologies that can potentially provide an unlimited source of cells for cell replacement therapy in the treatment of retinal degenerative disorders such as age-related macular degeneration (AMD), Stargardt disease, and other disorders. ESCs and iPSCs have been used to generate retinal pigment epithelium (RPE) cells and their functional behavior has been tested in vitro and in vivo in animal models. Additionally, iPSC-derived RPE cells provide an autologous source of cells for therapeutic use, as well as allow for novel approaches in disease modeling and drug development platforms. Clinical trials are currently testing the safety and efficacy of these cells in patients with AMD. In this review, the current status of iPSC disease modeling of AMD is discussed, as well as the challenges and potential of this technology as a viable option for cell replacement therapy in retinal degeneration. |
| first_indexed | 2024-03-12T07:59:25Z |
| format | Article |
| id | doaj.art-f444e0a892094dcf9b3c3200fe04cf77 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-12T07:59:25Z |
| publishDate | 2016-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-f444e0a892094dcf9b3c3200fe04cf772023-09-02T20:00:49ZengMDPI AGCells2073-44092016-12-01544410.3390/cells5040044cells5040044Potential of Induced Pluripotent Stem Cells (iPSCs) for Treating Age-Related Macular Degeneration (AMD)Mark Fields0Hui Cai1Jie Gong2Lucian Del Priore3Department of Ophthalmology and Visual Science, Yale School of Medicine, Yale University, 300 George St., Suite 8100, New Haven, CT 06511, USADepartment of Ophthalmology and Visual Science, Yale School of Medicine, Yale University, 300 George St., Suite 8100, New Haven, CT 06511, USADepartment of Ophthalmology and Visual Science, Yale School of Medicine, Yale University, 300 George St., Suite 8100, New Haven, CT 06511, USADepartment of Ophthalmology and Visual Science, Yale School of Medicine, Yale University, 300 George St., Suite 8100, New Haven, CT 06511, USAThe field of stem cell biology has rapidly evolved in the last few decades. In the area of regenerative medicine, clinical applications using stem cells hold the potential to be a powerful tool in the treatment of a wide variety of diseases, in particular, disorders of the eye. Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are promising technologies that can potentially provide an unlimited source of cells for cell replacement therapy in the treatment of retinal degenerative disorders such as age-related macular degeneration (AMD), Stargardt disease, and other disorders. ESCs and iPSCs have been used to generate retinal pigment epithelium (RPE) cells and their functional behavior has been tested in vitro and in vivo in animal models. Additionally, iPSC-derived RPE cells provide an autologous source of cells for therapeutic use, as well as allow for novel approaches in disease modeling and drug development platforms. Clinical trials are currently testing the safety and efficacy of these cells in patients with AMD. In this review, the current status of iPSC disease modeling of AMD is discussed, as well as the challenges and potential of this technology as a viable option for cell replacement therapy in retinal degeneration.http://www.mdpi.com/2073-4409/5/4/44age-related macular degenerationinduced pluripotent stem cellretinal pigment epitheliumBruch’s membranedisease modeling |
| spellingShingle | Mark Fields Hui Cai Jie Gong Lucian Del Priore Potential of Induced Pluripotent Stem Cells (iPSCs) for Treating Age-Related Macular Degeneration (AMD) Cells age-related macular degeneration induced pluripotent stem cell retinal pigment epithelium Bruch’s membrane disease modeling |
| title | Potential of Induced Pluripotent Stem Cells (iPSCs) for Treating Age-Related Macular Degeneration (AMD) |
| title_full | Potential of Induced Pluripotent Stem Cells (iPSCs) for Treating Age-Related Macular Degeneration (AMD) |
| title_fullStr | Potential of Induced Pluripotent Stem Cells (iPSCs) for Treating Age-Related Macular Degeneration (AMD) |
| title_full_unstemmed | Potential of Induced Pluripotent Stem Cells (iPSCs) for Treating Age-Related Macular Degeneration (AMD) |
| title_short | Potential of Induced Pluripotent Stem Cells (iPSCs) for Treating Age-Related Macular Degeneration (AMD) |
| title_sort | potential of induced pluripotent stem cells ipscs for treating age related macular degeneration amd |
| topic | age-related macular degeneration induced pluripotent stem cell retinal pigment epithelium Bruch’s membrane disease modeling |
| url | http://www.mdpi.com/2073-4409/5/4/44 |
| work_keys_str_mv | AT markfields potentialofinducedpluripotentstemcellsipscsfortreatingagerelatedmaculardegenerationamd AT huicai potentialofinducedpluripotentstemcellsipscsfortreatingagerelatedmaculardegenerationamd AT jiegong potentialofinducedpluripotentstemcellsipscsfortreatingagerelatedmaculardegenerationamd AT luciandelpriore potentialofinducedpluripotentstemcellsipscsfortreatingagerelatedmaculardegenerationamd |